– BELGIUM, Ghent – ExeVir today announced the appointment of Dr. Jeanne Bolger as Chair to its Board of Directors.
“We are extremely pleased to welcome Jeanne as Chair of the Board at such a pivotal time for the Company. Jeanne has an unparalleled track record in the pharmaceutical industry with exceptional expertise in leadership, driving innovation and R&D, and bringing Commercial and Business Development and significant venture experience. We look forward to working with Jeanne to drive ExeVir’s emerging pipeline forward.” said CEO, Dr. Torsten Mummenbrauer.
About Dr. Jeanne Bolger
Dr. Bolger has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development and Venture Investments at Johnson & Johnson Innovation – JJDC and at GlaxoSmithKline. She has been leading investments across Europe in start-up and early-stage life science companies and represented JJDC on the Board of Directors of over a dozen companies. She is also a Venture Partner at Seroba Life Sciences Venture Capital and serves on several government task forces and advisory boards. She is a visiting lecturer in the MSc Pharmaceutical Medicine program at Trinity College Dublin. Dr. Bolger received her medical degree from University College Dublin. She is a Fellow of the Royal Academy of Medicine of Ireland.
Dr. Jeanne Bolger said: “I am delighted to join ExeVir and support the team of leading scientists and entrepreneurs working on research to develop novel treatments for infectious diseases. As genetic pressure increases leading to potential viral mutant escape, ExeVir’s new pipeline is in an advantageous position for the long term. I look forward to adding my experience to support their mission in the international effort against COVID-19 and other emerging diseases of importance to global public health such as dengue fever.”
About ExeVir Bio
ExeVir Bio is a clinical-stage company developing nanobody-based therapeutics focusing on infectious diseases. ExeVir Bio, is a spin-out of VIB, the leading Belgium-based life sciences research institute, harnessing its Llama-derived antibody technology platform to generate multi-specific antibodies for prophylaxis and treatment of infectious diseases. ExeVir’s focus is on infectious diseases that lead to severe outcomes in a targeted population that does not benefit or is unable to benefit from vaccination, including migrating diseases due to global warming and urbanization.
this can be linked together like building blocks into a single molecule to tackle different epitopes or act through different mechanisms of action at once, to address the “arms race” in more complex and co-evolving infectious diseases. VHHs are smaller in size giving them access to hidden epitopes that traditional monoclonal antibodies are unable to reach with the potential for deeper tissue penetration and simple, cost-effective manufacturing.
ExeVir is building an exciting progressive pipeline with its initial focus on SARS COV-1 & 2 in the immunocompromised. It has progressed XVR011 from research to the clinic in less than 1 year and has completed Phase 1a and Phase 1b studies. This showed that ExeVir was able to take an asset very rapidly from its research platform through to the clinic. The compound showed good pharmacodynamics and efficient GMP manufacturability.
The Company has extremely promising molecules in preclinical development that are differentiated in targeting both S1 and S2 regions of the SARS-CoV-2 spike protein, demonstrating neutralization of all viral variants in circulation, including Omicron BA.5, currently the dominant variant circulating globally. These molecules can be used both as a therapeutic and prophylactic.
In addition to its SARS-CoV-2 programs, ExeVir has initiated research in dengue, a disease which is rapidly and progressively expanding.
ExeVir is backed by strong investors: Fund+, a leading EU Life Sciences-focused investment firm in Belgium which led the Series A of € 42M pulling together a strong consortium including UCB Ventures, FPIM, V-Bio Ventures, VIB, SRIW, Noshaq, Vives IUF, and SambrInvest. In addition, more recently ExeVir received in addition to its Vlaio grant, support from the SPW-Recherche and the European Union, leading to a total of €16.5M in non-dilutive funding.
For more information: https://exevir.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
